NCT01533116

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Bial - Portela C S.A. · Industry
• Sex: All
• Age: 25 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics

Detailed description

Single centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of healthy subjects

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	BIA 9-1067
DRUG	Placebo
DRUG	levodopa/carbidopa
DRUG	levodopa/benserazide

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-08-01
• Completion: 2010-03-01
• First posted: 2012-02-15
• Last updated: 2015-11-16
• Results posted: 2015-11-16

Locations

1 site across 1 country: Canada